Search Orphan Drug Designations and Approvals
-
Generic Name: | BMEDA-chelated Rhenium-186 nanoliposomes |
---|---|
Date Designated: | 11/02/2023 |
Orphan Designation: | Treatment of breast cancer with leptomeningeal metastases (LM) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Plus Therapeutics, Inc. 4200 Marathon Blvd. # 200 Austin, Texas 78756 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-